A. Clark

发表

Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH S

R. Kaiser, J. Gatell, K. Ruxrungtham, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Clinical Relevance of CYP3A5 Genotype on Maraviroc Exposures

L. Mcfadyen, M. Vourvahis, J. Heera, 2015, Drug Metabolism and Disposition.

Prevalence and Outcomes for Heavily Treatment-Experienced Individuals Living With Human Immunodeficiency Virus in a European Cohort

R. Paredes, J. Reekie, J. Weber, 2021, Journal of acquired immune deficiency syndromes.

Susceptibility of global HIV-1 clinical isolates to fostemsavir using the PhenoSense® Entry assay

M. Krystal, C. Llamoso, A. Clark, 2020, The Journal of antimicrobial chemotherapy.

Towards a Maraviroc long‐acting injectable nanoformulation

Lee M. Tatham, S. Rannard, A. Owen, 2019, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

Comparative Efficacy and Safety of Fostemsavir in Heavily Treatment-Experienced People With HIV-1.

S. Anderson, A. Clark, D. Browning, 2022, Clinical therapeutics.

Fostemsavir in Heavily Treatment-Experienced Individuals Living with HIV-1: Insights from the Phase 3 BRIGHTE Study

M. Kozal, T. Schoofs, A. Clark, 2021, Journal of AIDS and HIV Treatment.

Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment

C. Fichtenbaum, H. Stellbrink, M. Saag, 2016, AIDS.

No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV‐1–Infected Subjects

J. Marshall, P. Chan, S. Nepal, 2018, Journal of clinical pharmacology.

Patient-Reported Outcomes in the Phase III BRIGHTE Trial of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Individuals

D. Cella, M. Murray, S. Anderson, 2021, The Patient - Patient-Centered Outcomes Research.

Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1

M. Kozal, P. Cahn, M. Krystal, 2022, Antimicrobial agents and chemotherapy.

Effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection: a large-scale systematic review

N. Hill, G. Dusheiko, A. Clark, 2017, BMC Infectious Diseases.

1264. Durability and effectiveness of fostemsavir in heavily treatment-experienced people with HIV

V. Vannappagari, R. Hsu, L. Brunet, 2022, Open Forum Infectious Diseases.

Temsavir blocks the immunomodulatory activities of HIV-1 soluble gp120.

D. Kaufmann, M. Pazgier, W. Tolbert, 2023, Cell chemical biology.

Dolutegravir-based regimens in treatment-naive and treatment-experienced aging populations: analyses of 6 phase III clinical trials

B. Wynne, M. van der Kolk, R. Grove, 2021, HIV research & clinical practice.

The evolution of clinical study design in heavily treatment-experienced persons with HIV: A critical review

J. Aberg, S. Moreno, A. Clark, 2023, Antiviral therapy.

Temsavir Treatment of HIV-1-Infected Cells Decreases Envelope Glycoprotein Recognition by Broadly Neutralizing Antibodies

D. Vézina, J. Richard, S. Anand, 2022, mBio.

Improving maraviroc oral bioavailability by formation of solid drug nanoparticles

Lee M. Tatham, S. Rannard, A. Owen, 2019, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1

C. Giaquinto, L. Mcfadyen, C. Craig, 2017, The Pediatric infectious disease journal.